The wonders of X-PDT: an advance route to cancer theranostics.


Journal

Journal of nanobiotechnology
ISSN: 1477-3155
Titre abrégé: J Nanobiotechnology
Pays: England
ID NLM: 101152208

Informations de publication

Date de publication:
25 Oct 2024
Historique:
received: 01 07 2024
accepted: 11 10 2024
medline: 26 10 2024
pubmed: 26 10 2024
entrez: 26 10 2024
Statut: epublish

Résumé

Global mortality data indicates cancer as the second-leading cause of death worldwide. Therefore, there's a pressing need to innovate effective treatments to address this significant medical and societal challenge. In recent years, X-ray-induced photodynamic therapy (X-PDT) has emerged as a promising advancement, revolutionizing traditional photodynamic therapy (PDT) for deeply entrenched malignancies by harnessing penetrating X-rays as external stimuli. Recent developments in X-ray photodynamic therapy have shown a trend toward minimizing radiation doses to remarkably low levels after the proof-of-concept demonstration. Early detection and real-time monitoring are crucial aspects of effective cancer treatment. Sophisticated X-ray imaging techniques have been enhanced by the introduction of X-ray luminescence nano-agents, alongside contrast nanomaterials based on X-ray attenuation. X-ray luminescence-based in vivo imaging offers excellent detection sensitivity and superior image quality in deep tissues at a reasonable cost, due to unhindered penetration and unimpeded auto-fluorescence of X-rays. This review emphasizes the significance of X-ray responsive theranostics, exploring their mechanism of action, feasibility, biocompatibility, and promising prospects in imaging-guided therapy for deep-seated tumors. Additionally, it discusses promising applications of X-PDT in treating breast cancer, liver cancer, lung cancer, skin cancer, and colorectal cancer.

Identifiants

pubmed: 39456085
doi: 10.1186/s12951-024-02931-5
pii: 10.1186/s12951-024-02931-5
doi:

Substances chimiques

Photosensitizing Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

655

Subventions

Organisme : the Postdoctoral funding Grant
ID : 02080100-K3F113001
Organisme : the National Natural Science Foundation of China
ID : T2293753
Organisme : the 2023 Hangzhou West Lake Pearl Project Leading Innovative Youth Team Project
ID : TD2023017

Informations de copyright

© 2024. The Author(s).

Références

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33.
pubmed: 35020204 doi: 10.3322/caac.21708
Mattiuzzi C, Lippi G. Current Cancer Epidemiology glossary. J Epidemiol Glob Health. 2019;9:217–22.
pubmed: 31854162 pmcid: 7310786 doi: 10.2991/jegh.k.191008.001
Debien V, De Caluwé A, Wang X, Piccart-Gebhart M, Tuohy VK, Romano E, et al. Immunotherapy in breast cancer: an overview of current strategies and perspectives. NPJ Breast Cancer. 2023;9:1–10.
doi: 10.1038/s41523-023-00508-3
Li X, Ramadori P, Pfister D, Seehawer M, Zender L, Heikenwalder M. The immunological and metabolic landscape in primary and metastatic liver cancer. Nat Rev Cancer. 2021;21:541–57.
pubmed: 34326518 doi: 10.1038/s41568-021-00383-9
Oudkerk M, Liu SY, Heuvelmans MA, Walter JE, Field JK. Lung cancer LDCT screening and mortality reduction—evidence, pitfalls and future perspectives. Nat Rev Clin Oncol. 2021;18:135–51.
pubmed: 33046839 doi: 10.1038/s41571-020-00432-6
Schlumberger M, Leboulleux S. Current practice in patients with differentiated thyroid cancer. Nat Rev Endocrinol. 2021;17:176–88.
pubmed: 33339988 doi: 10.1038/s41574-020-00448-z
Gandaglia G, Leni R, Bray F, Fleshner N, Freedland SJ, Kibel A, et al. Epidemiology and prevention of prostate cancer. Eur Urol Oncol. 2021;4:877–92.
pubmed: 34716119 doi: 10.1016/j.euo.2021.09.006
Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health. 2023;11:e197–206.
pubmed: 36528031 doi: 10.1016/S2214-109X(22)00501-0
Van HLMC, Vrieling A, Van Der HAG, Kogevinas M, Richters A, Kiemeney LA. Global trends in the epidemiology of bladder cancer : challenges for public health and clinical practice. Nat Rev Clin Oncol. 2023;20:287–304.
doi: 10.1038/s41571-023-00744-3
Esmeeta A, Adhikary S, Dharshnaa V, Swarnamughi P, Ummul Maqsummiya Z, Banerjee A, et al. Plant-derived bioactive compounds in colon cancer treatment: an updated review. Biomed Pharmacother. 2022;153: 113384.
pubmed: 35820317 doi: 10.1016/j.biopha.2022.113384
Mirza MR, Chase DM, Slomovitz BM, dePont CR, Novák Z, Black D, et al. Dostarlimab for primary advanced or recurrent endometrial cancer. N Engl J Med. 2023;388:2145–58.
pubmed: 36972026 doi: 10.1056/NEJMoa2216334
Choueiri TK, Albiges L, Atkins MB, Bakouny Z, Bratslavsky G, Braun DA, et al. From basic science to clinical translation in kidney cancer: a report from the second kidney cancer research summit. Clin Cancer Res. 2022;28:831–9.
pubmed: 34965942 pmcid: 9223120 doi: 10.1158/1078-0432.CCR-21-3238
Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388:1002–14.
pubmed: 36762851 doi: 10.1056/NEJMoa2213614
Armitage JO, Long DL. Mantle-cell lymphoma. N Engl J Med. 2022;386:2495–506.
pubmed: 35767440 doi: 10.1056/NEJMra2202672
Hingorani SR. Epithelial and stromal co-evolution and complicity in pancreatic cancer. Nat Rev Cancer. 2023;23:57–77.
pubmed: 36446904 doi: 10.1038/s41568-022-00530-w
Brown JR, Eichhorst B, Hillmen P, Jurczak W, Kaźmierczak M, Lamanna N, et al. Zanubrutinib or Ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388:319–32.
pubmed: 36511784 doi: 10.1056/NEJMoa2211582
Patel SP, Othus M, Chen Y, Wright GP, Yost KJ, Hyngstrom JR, et al. Neoadjuvant–adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med. 2023;388:813–23.
pubmed: 36856617 pmcid: 10410527 doi: 10.1056/NEJMoa2211437
Nakhoda S, Vistarop A, Wang YL. Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. Br J Haematol. 2023;200:137–49.
pubmed: 36029036 doi: 10.1111/bjh.18418
Pashayan N, Pharoah PDP. The challenge of early detection in cancer. Science. 1979;2020(368):589–90.
Li X, Bao Y, Li Z, Teng P, Ma L, Zhang H, et al. Employing antagonistic C-X-C motif chemokine receptor 4 antagonistic peptide functionalized NaGdF
pubmed: 38982161 pmcid: 11233619 doi: 10.1038/s41598-024-66645-2
Kumar Sarangi M, Padhi S, Rath G, Sekhar Nanda S, Kee YD. Advances in immunological and theranostic approaches of gold nanoparticles—a review. Inorg Chem Commun. 2023;153:110858.
doi: 10.1016/j.inoche.2023.110858
Dutta Gupta Y, Mackeyev Y, Krishnan S, Bhandary S. Mesoporous silica nanotechnology: promising advances in augmenting cancer theranostics. Cancer Nanotechnol. 2024;15:1–44.
doi: 10.1186/s12645-024-00250-w
Hosseini SM, Mohammadnejad J, Salamat S, Beiram Zadeh Z, Tanhaei M, Ramakrishna S. Theranostic polymeric nanoparticles as a new approach in cancer therapy and diagnosis: a review. Mater Today Chem. 2023;29: 101400.
doi: 10.1016/j.mtchem.2023.101400
Yukawa H, Sato K, Baba Y. Theranostics applications of quantum dots in regenerative medicine, cancer medicine, and infectious diseases. Adv Drug Deliv Rev. 2023;200:114863.
pubmed: 37156265 doi: 10.1016/j.addr.2023.114863
Ma Q, Cao Y, Ge X, Zhang Z, Gao S, Song J. X-ray excited luminescence materials for cancer diagnosis and theranostics. Laser Photon Rev. 2024;18:2300565.
doi: 10.1002/lpor.202300565
Al-Thani AN, Jan AG, Abbas M, Geetha M, Sadasivuni KK. Nanoparticles in cancer theragnostic and drug delivery: a comprehensive review. Life Sci. 2024;352: 122899.
pubmed: 38992574 doi: 10.1016/j.lfs.2024.122899
Rahimkhoei V, Alzaidy AH, Abed MJ, Rashki S, Salavati-Niasari M. Advances in inorganic nanoparticles-based drug delivery in targeted breast cancer theranostics. Adv Colloid Interface Sci. 2024;329: 103204.
pubmed: 38797070 doi: 10.1016/j.cis.2024.103204
Jin GQ, Chau CV, Arambula JF, Gao S, Sessler JL, Zhang JL. Lanthanide porphyrinoids as molecular theranostics. Chem Soc Rev. 2022;51:6177–209.
pubmed: 35792133 doi: 10.1039/D2CS00275B
Domingues I, Pereira G, Martins P, Duarte H, Santos J, Abreu PH. Using deep learning techniques in medical imaging: a systematic review of applications on CT and PET. Artif Intell Rev. 2020;53:4093–160.
doi: 10.1007/s10462-019-09788-3
Hsu JC, Nieves LM, Betzer O, Sadan T, Noël PB, Popovtzer R, et al. Nanoparticle contrast agents for X-ray imaging applications. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020;12:1–26.
doi: 10.1002/wnan.1642
Wu Q, Zheng Q, He Y, Chen Q, Yang H. Emerging nanoagents for medical x-ray imaging. Anal Chem. 2023;95:33–48.
pubmed: 36625104 doi: 10.1021/acs.analchem.2c04602
Sun W, Zhou Z, Pratx G, Chen X, Chen H. Nanoscintillator-mediated X-ray induced photodynamic therapy for deep-seated tumors: from concept to biomedical applications. Theranostics. 2020;10:1296–318.
pubmed: 31938066 pmcid: 6956812 doi: 10.7150/thno.41578
Yu X, Liu X, Yang K, Chen X, Li W. Pnictogen semimetal (Sb, Bi)-based nanomaterials for cancer imaging and therapy: a materials perspective. ACS Nano. 2021;15:2038–67.
pubmed: 33486944 doi: 10.1021/acsnano.0c07899
Pires L, Calcada C, Grafinger O, Juneja R, Mar S, Leong H, et al. Photosensitizers as radiosensitizers for metastatic and deep-seated tumors: in vitro and ex-ovo preclinical studies. Photodiagnosis Photodyn Ther. 2023;41: 103422.
doi: 10.1016/j.pdpdt.2023.103422
Belanova A, Chmykhalo V, Beseda D, Belousova M, Butova V, Soldatov A, et al. A mini-review of X-ray photodynamic therapy (XPDT) nonoagent constituents’ safety and relevant design considerations. Photochem Photobiol Sci. 2020;19:1134–44.
pubmed: 32776036 doi: 10.1039/c9pp00456d
Fan W, Huang P, Chen X. Overcoming the Achilles’ heel of photodynamic therapy. Chem Soc Rev. 2016;45:6488–519.
pubmed: 27722560 doi: 10.1039/C6CS00616G
Chen X, Song J, Chen X, Yang H. X-ray-activated nanosystems for theranostic applications. Chem Soc Rev. 2019;48:3073–101.
pubmed: 31106315 doi: 10.1039/C8CS00921J
Kirakci K, Kubát P, Fejfarova K, Martinčík J, Nikl M, Lang K. X-ray inducible luminescence and singlet oxygen sensitization by an octahedral molybdenum cluster compound: a new class of nanoscintillators. Inorg Chem. 2016;55:803–9.
pubmed: 26702498 doi: 10.1021/acs.inorgchem.5b02282
Lei L, Wang Y, Kuzmin A, Hua Y, Zhao J, Xu S, et al. Next generation lanthanide doped nanoscintillators and photon converters. eLight. 2022;2:1–24.
doi: 10.1186/s43593-022-00024-0
Bulin A-L, Vasil’ev A, Belsky A, Amans D, Ledoux G, Dujardin C. Modelling energy deposition in nanoscintillators to predict the efficiency of the X-ray-induced photodynamic effect. Nanoscale. 2015;7:5744–51.
pubmed: 25746211 doi: 10.1039/C4NR07444K
Yu X, Liu X, Wu W, Yang K, Mao R, Ahmad F, et al. CT/MRI-guided synergistic radiotherapy and X-ray inducible photodynamic therapy using Tb-doped Gd-W-nanoscintillators. Angew Chem. 2019;131:2039–44.
doi: 10.1002/ange.201812272
Song G, Cheng L, Chao Y, Yang K, Liu Z. Emerging nanotechnology and advanced materials for cancer radiation therapy. Adv Mater. 2017;29:1–26.
doi: 10.1002/adma.201700996
Shen S, Jiang D, Cheng L, Chao Y, Nie K, Dong Z, et al. Renal-clearable ultrasmall coordination polymer nanodots for chelator-free
pubmed: 28853861 pmcid: 5617799 doi: 10.1021/acsnano.7b03857
Zhang XD, Chen J, Min Y, Park GB, Shen X, Song SS, et al. Metabolizable Bi
doi: 10.1002/adfm.201302312
Gong T, Li Y, Lv B, Wang H, Liu Y, Yang W, et al. Full-process radiosensitization based on nanoscale metal-organic frameworks. ACS Nano. 2020;14:3032–40.
pubmed: 32150395 doi: 10.1021/acsnano.9b07898
Yang B, Chen Y, Shi J. Reactive oxygen species (ROS)-based nanomedicine. Chem Rev. 2019;119:4881–985.
pubmed: 30973011 doi: 10.1021/acs.chemrev.8b00626
Kirsanova DY, Gadzhimagomedova ZM, Maksimov AY, Soldatov AV. Nanomaterials for deep tumor treatment. Mini Rev Med Chem. 2021;21:677–88.
pubmed: 33176645 doi: 10.2174/1389557520666201111161705
Popovich K, Procházková L, Pelikánová IT, Vlk M, Palkovský M, Jarý V, et al. Preliminary study on singlet oxygen production using CeF
doi: 10.1016/j.radmeas.2016.01.033
Zhang Q, Guo X, Cheng Y, Chudal L, Pandey NK, Zhang J, et al. Use of copper-cysteamine nanoparticles to simultaneously enable radiotherapy, oxidative therapy and immunotherapy for melanoma treatment. Signal Transduct Target Ther. 2020;5:4–6.
Ma L, Zou X, Chen W. A new X-ray activated nanoparticle photosensitizer for cancer treatment. J Biomed Nanotechnol. 2014;10:1501–8.
pubmed: 25016650 doi: 10.1166/jbn.2014.1954
Ma L, Zou X, Bui B, Chen W, Song KH, Solberg T. X-ray excited ZnS:Cu, Co afterglow nanoparticles for photodynamic activation. Appl Phys Lett. 2014;105: 013702.
doi: 10.1063/1.4890105
Gadzhimagomedova Z, Zolotukhin P, Kit O, Kirsanova D, Soldatov A. Nanocomposites for X-ray photodynamic therapy. Int J Mol Sci. 2020;21:1–15.
doi: 10.3390/ijms21114004
Sengar P, Garcia-Tapia K, Chauhan K, Jain A, Juarez-Moreno K, Borbón-Nuñez HA, et al. Dualphotosensitizer coupled nanoscintillator capable of producing type I and type II ROS for next generation photodynamic therapy. J Colloid Interface Sci. 2019;536:586–97.
pubmed: 30390584 doi: 10.1016/j.jcis.2018.10.090
Zhang W, Zhang X, Shen Y, Shi F, Song C, Liu T, et al. Ultra-high FRET efficiency NaGdF
pubmed: 30195803 doi: 10.1016/j.biomaterials.2018.09.001
Chen MH, Jenh YJ, Wu SK, Chen YS, Hanagata N, Lin FH. Non-invasive photodynamic therapy in brain cancer by use of Tb
doi: 10.1186/s11671-017-1840-3
Elmenoufy AH, Tang Y, Hu J, Xu H, Yang X. A novel deep photodynamic therapy modality combined with CT imaging established via X-ray stimulated silica-modified lanthanide scintillating nanoparticles. Chem Commun. 2015;51:12247–50.
doi: 10.1039/C5CC04135J
Bulin A-L, Truillet C, Chouikrat R, Lux F, Frochot C, Amans D, et al. X-ray-induced singlet oxygen activation with nanoscintillator-coupled porphyrins. J Phys Chem C. 2013;117:21583–9.
doi: 10.1021/jp4077189
Kaščáková S, Giuliani A, Lacerda S, Pallier A, Mercère P, Tóth É, et al. X-ray-induced radiophotodynamic therapy (RPDT) using lanthanide micelles: beyond depth limitations. Nano Res. 2015;8:2373–9.
doi: 10.1007/s12274-015-0747-5
Zhang X, Lan B, Wang S, Gao P, Liu T, Rong J, et al. Low-dose X-ray excited photodynamic therapy based on NaLuF
pubmed: 31344330 doi: 10.1021/acs.bioconjchem.9b00429
Popovich K, Tomanová K, Čuba V, Procházková L, Pelikánová IT, Jakubec I, et al. LuAG:Pr
pubmed: 29413988 doi: 10.1016/j.jphotobiol.2018.01.015
Procházková L, Pelikánová IT, Mihóková E, Dědic R, Čuba V. Novel scintillating nanocomposite for X-ray induced photodynamic therapy. Radiat Meas. 2019;121:13–7.
doi: 10.1016/j.radmeas.2018.12.008
Procházková L, Čuba V, Beitlerová A, Jarý V, Omelkov S, Nikl M. Ultrafast Zn(Cd, Mg)O: Ga nanoscintillators with luminescence tunable by band gap modulation. Opt Express. 2018;26:29482–94.
pubmed: 30470111 doi: 10.1364/OE.26.029482
Wang GD, Nguyen HT, Chen H, Cox PB, Wang L, Nagata K, et al. X-ray induced photodynamic therapy: a combination of radiotherapy and photodynamic therapy. Theranostics. 2016;6:2295–305.
pubmed: 27877235 pmcid: 5118595 doi: 10.7150/thno.16141
Bekah D, Cooper D, Kudinov K, Hill C, Seuntjens J, Bradforth S, et al. Synthesis and characterization of biologically stable, doped LaF
doi: 10.1016/j.jphotochem.2016.06.008
Zou X, Yao M, Ma L, Hossu M, Han X, Juzenas P, et al. X-ray-induced nanoparticle-based photodynamic therapy of cancer. Nanomedicine. 2014;9:2339–51.
pubmed: 24471504 doi: 10.2217/nnm.13.198
Sapre AA, Novitskaya E, Vakharia V, Cota A, Wrasidlo W, Hanrahan SM, et al. Optimized scintillator YAG: Pr nanoparticles for X-ray inducible photodynamic therapy. Mater Lett. 2018;228:49–52.
pubmed: 30505045 pmcid: 6258075 doi: 10.1016/j.matlet.2018.05.090
Kaszewski J, Olszewski J, Rosowska J, Witkowski B, Wachnicki Ł, Wenelska K, et al. HfO
doi: 10.1016/j.jre.2019.04.003
Li X, Xue Z, Jiang M, Li Y, Zeng S, Liu H. Soft X-ray activated NaYF
doi: 10.1039/C7NR02926H
Generalov R, Kuan WB, Chen W, Kristensen S, Juzenas P. Radiosensitizing effect of zinc oxide and silica nanocomposites on cancer cells. Colloids Surf B Biointerfaces. 2015;129:79–86.
pubmed: 25829130 doi: 10.1016/j.colsurfb.2015.03.026
Zagami P, Carey LA. Triple negative breast cancer: pitfalls and progress. NPJ Breast Cancer. 2022;8:1–10.
doi: 10.1038/s41523-022-00468-0
Perou CM, Sorlie T, Eisen MB, Van De RM, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;533:747–52.
doi: 10.1038/35021093
Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell. 2019;173:291–304.
doi: 10.1016/j.cell.2018.03.022
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386:556–67.
pubmed: 35139274 doi: 10.1056/NEJMoa2112651
Wang X, Sun W, Shi H, Ma H, Niu G, Li Y, et al. Organic phosphorescent nanoscintillator for low-dose X-ray-induced photodynamic therapy. Nat Commun. 2022;13:1–9.
Zhang B, Liu H, Wang Y, Zhang Y, Cheng J. Application of singlet oxygen-activatable nanocarriers to boost X-ray-induced photodynamic therapy and cascaded ferroptosis for breast cancer treatment. J Mater Chem B. 2023;11:9685–96.
pubmed: 37789698 doi: 10.1039/D3TB01887C
Jain A, Koyani R, Muñoz C, Sengar P, Contreras OE, Juárez P, et al. Magnetic-luminescent cerium-doped gadolinium aluminum garnet nanoparticles for simultaneous imaging and photodynamic therapy of cancer cells. J Colloid Interface Sci. 2018;526:220–9.
pubmed: 29734089 doi: 10.1016/j.jcis.2018.04.100
Maiti D, Yu H, Kim BS, Naito M, Yamashita S, Kim HJ, et al. Rose Bengal decorated NaYF
pubmed: 36318743 doi: 10.1021/acsabm.2c00801
Maiti D, Yu H, Mochida Y, Won S, Yamashita S, Naito M, et al. Terbium-Rose Bengal coordination nanocrystals-induced ROS production under low-dose X-rays in cultured cancer cells for photodynamic therapy. ACS Appl Bio Mater. 2023;6:2505–13.
pubmed: 37289471 doi: 10.1021/acsabm.3c00304
Chen X, Liu J, Li Y, Pandey NK, Chen T, Wang L, et al. Study of copper-cysteamine based X-ray induced photodynamic therapy and its effects on cancer cell proliferation and migration in a clinical mimic setting. Bioact Mater. 2022;7:504–14.
pubmed: 34466749
Zhang B, Xue R, Lyu J, Gao A, Sun C. Tumor acidity/redox hierarchical-activable nanoparticles for precise combination of X-ray-induced photodynamic therapy and hypoxia-activated chemotherapy. J Mater Chem B. 2022;10:3849–60.
pubmed: 35470367 doi: 10.1039/D2TB00303A
Sengar P, Juárez P, Meza AV, Arellano DL, Jain A, Chauhan K, et al. Development of a functionalized UV-emitting nanocomposite for the treatment of cancer using indirect photodynamic therapy. J Nanobiotechnol. 2018;16:1–19.
doi: 10.1186/s12951-018-0344-3
Jiang F, Lee C, Zhang W, Jiang W, Cao Z, Chong HB, et al. Radiodynamic therapy with CsI(na)@MgO nanoparticles and 5-aminolevulinic acid. J Nanobiotechno. 2022;20:1–15.
doi: 10.1186/s12951-022-01537-z
Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380:1450–62.
pubmed: 30970190 doi: 10.1056/NEJMra1713263
Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol. 2010;7:448–58.
pubmed: 20628345 pmcid: 3926946 doi: 10.1038/nrgastro.2010.100
Sia D, Villanueva A, Friedman SL, Llovet JM. Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology. 2017;152:745–61.
pubmed: 28043904 doi: 10.1053/j.gastro.2016.11.048
Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60:1268–89.
pubmed: 24681130 doi: 10.1016/j.jhep.2014.01.021
Cao J, Wang J, He C, Fang M. Angiosarcoma: a review of diagnosis and current treatment. Am J Cancer Res. 2019;9:2303–13.
pubmed: 31815036 pmcid: 6895451
Fitzmaurice C, Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level results from the global burden of disease study 2015. JAMA Oncol. 2017;3:1683–91.
pubmed: 28983565 pmcid: 5824275 doi: 10.1001/jamaoncol.2017.3055
Celsa C, Stornello C, Giuffrida P, Giacchetto CM, Grova M, Rancatore G, et al. Direct-acting antiviral agents and risk of Hepatocellular carcinoma: critical appraisal of the evidence. Ann Hepatol. 2022;27: 100568.
pubmed: 34699987 doi: 10.1016/j.aohep.2021.100568
Zhen X, Pandey NK, Amador E, Hu W, Liu B, Nong W, et al. Potassium iodide enhances the anti-hepatocellular carcinoma effect of copper-cysteamine nanoparticle mediated photodynamic therapy on cancer treatment. Mater Today Phys. 2022;27: 100838.
doi: 10.1016/j.mtphys.2022.100838
Vasuri F, Renzulli M, Fittipaldi S, Brocchi S, Clemente A, Cappabianca S, et al. Pathobiological and radiological approach for hepatocellular carcinoma subclassification. Sci Rep. 2019;9:1–10.
doi: 10.1038/s41598-019-51303-9
Mushtaq A, Iqbal MZ, Kong X. Antiviral effects of coinage metal-based nanomaterials to combat COVID-19 and its variants. J Mater Chem B. 2022;10:5323–43.
pubmed: 35775993 doi: 10.1039/D2TB00849A
Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. The Lancet. 2021;398:535–54.
doi: 10.1016/S0140-6736(21)00312-3
Araujo LH, Horn L, Merritt RE, Shilo K, Xu-Welliver M, Carbone DP. 69—Cancer of the lung: non-small cell lung cancer and small cell lung cancer. In: Niederhuber JE, Armitage JO, Kastan MB, Doroshow JH, Tepper JE, editors. Abeloff’s clinical oncology. Amsterdam: Elsevier; 2020.
Jiang Y, Su Z, Liang H, Liu J, Liang W, He J. Video-assisted thoracoscopy for lung cancer: Who is the future of thoracic surgery? J Thorac Dis. 2020;12:4427–33.
pubmed: 32944356 pmcid: 7475530 doi: 10.21037/jtd-20-1116
Baker S, Dahele M, Lagerwaard FJ, Senan S. A critical review of recent developments in radiotherapy for non-small cell lung cancer. Radiat Oncol. 2016;11:1–14.
doi: 10.1186/s13014-016-0693-8
Yang CC, Wang WY, Lin FH, Hou CH. Rare-earth-doped calcium carbonate exposed to X-ray irradiation to induce reactive oxygen species for tumor treatment. Int J Mol Sci. 2019;20:1148.
pubmed: 30845750 pmcid: 6429163 doi: 10.3390/ijms20051148
Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet. 2016;387:1540–50.
doi: 10.1016/S0140-6736(15)01281-7
Chen H, Sun X, Wang GD, Nagata K, Hao Z, Wang A, et al. LiGa
pubmed: 31528350 pmcid: 6746429 doi: 10.1039/C7MH00442G
Rossi F, Bedogni E, Bigi F, Rimoldi T, Cristofolini L, Pinelli S, et al. Porphyrin conjugated SiC/SiOx nanowires for X-ray-excited photodynamic therapy. Sci Rep. 2015;5:1–6.
doi: 10.1038/srep07606
Yang DM, Cvetkovic D, Chen L, Ma CMC. Therapeutic effects of in-vivo radiodynamic therapy (RDT) for lung cancer treatment: a combination of 15 MV photons and 5-aminolevulinic acid (5-ALA). Biomed Phys Eng Express. 2022;8: 065031.
doi: 10.1088/2057-1976/ac9b5c
Sanchez G, Nova J, Rodriguez-Hernandez AE, Solorzano-Restrepo C, Gonzalez J, Olmos M, et al. Sun protection for preventing basal cell and squamous cell skin cancers. Cochrane Database Syst Rev. 2016;2016:1–32.
Domingues B, Lopes JM, Soares P, Pópulo H. Melanoma treatment in review. Immunotargets Ther. 2018;7:35–49.
pubmed: 29922629 pmcid: 5995433 doi: 10.2147/ITT.S134842
Hu W, Fang L, Ni R, Zhang H, Pan G. Changing trends in the disease burden of non-melanoma skin cancer globally from 1990 to 2019 and its predicted level in 25 years. BMC Cancer. 2022;22:1–11.
doi: 10.1186/s12885-022-09940-3
Shi L, Liu P, Wu J, Ma L, Zheng H, Antosh MP, et al. The effectiveness and safety of X-PDT for cutaneous squamous cell carcinoma and melanoma. Nanomedicine. 2019;14:2027–43.
pubmed: 31165659 pmcid: 7006790 doi: 10.2217/nnm-2019-0094
Ma L, Chen W, Schatte G, Wang W, Joly AG, Huang Y, et al. A new Cu-cysteamine complex: structure and optical properties. J Mater Chem C Mater. 2014;2:4239–46.
doi: 10.1039/C4TC00114A
Pandey NK, Chudal L, Phan J, Lin L, Johnson O, Xing M, et al. A facile method for the synthesis of copper-cysteamine nanoparticles and study of ROS production for cancer treatment. J Mater Chem B. 2019;7:6630–42.
pubmed: 31591609 doi: 10.1039/C9TB01566C
Takahashi J, Murakami M, Mori T, Iwahashi H. Verification of radiodynamic therapy by medical linear accelerator using a mouse melanoma tumor model. Sci Rep. 2018;8:1–9.
Hasegawa T, Takahashi J, Nagasawa S, Doi M, Moriyama A, Iwahashi H. Dna strand break properties of protoporphyrin IX by X-ray irradiation against melanoma. Int J Mol Sci. 2020;21:2302.
pubmed: 32225109 pmcid: 7177738 doi: 10.3390/ijms21072302
Mármol I, Sánchez-de-Diego C, Dieste AP, Cerrada E, Yoldi MJR. Colorectal carcinoma: a general overview and future perspectives in colorectal cancer. Int J Mol Sci. 2017;18:197.
pubmed: 28106826 pmcid: 5297828 doi: 10.3390/ijms18010197
Sameer AS. Colorectal cancer: molecular mutations and polymorphisms. Front Oncol. 2013;3:114.
pubmed: 23717813 pmcid: 3651991 doi: 10.3389/fonc.2013.00114
Stintzing S. Management of colorectal cancer. Prime Rep. 2014;6:108.
Sang R, Deng F, Engel A, Goldys E, Deng W. Lipid-polymer nanocarrier platform enables X-ray induced photodynamic therapy against human colorectal cancer cells. Biomed Pharmacother. 2022;155: 113837.
pubmed: 36271586 doi: 10.1016/j.biopha.2022.113837
Lan G, Ni K, Xu R, Lu K, Lin Z, Chan C, et al. Nanoscale metal–organic layers for deeply penetrating X-ray-induced photodynamic therapy. Angew Chem. 2017;56:12102–6.
doi: 10.1002/anie.201704828
Deng W, McKelvey KJ, Guller A, Fayzullin A, Campbell JM, Clement S, et al. Application of mitochondrially targeted nanoconstructs to neoadjuvant X-ray-induced photodynamic therapy for rectal cancer. ACS Cent Sci. 2020;6:715–26.
pubmed: 32490188 pmcid: 7256935 doi: 10.1021/acscentsci.9b01121

Auteurs

Asim Mushtaq (A)

Institute for Intelligent Bio/Chem Manufacturing (iBCM), ZJU-Hangzhou Global Scientific and Technological Innovation Center, Hangzhou, 311200, Zhejiang, China.
College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, 310007, China.

Muhammad Zubair Iqbal (MZ)

Institute of Smart Biomedical Materials, School of Materials Science and Engineering, Zhejiang Sci-Tech University, Hangzhou, 310018, China.

Jianbin Tang (J)

Institute for Intelligent Bio/Chem Manufacturing (iBCM), ZJU-Hangzhou Global Scientific and Technological Innovation Center, Hangzhou, 311200, Zhejiang, China.
College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, 310007, China.

Wenjing Sun (W)

Institute for Intelligent Bio/Chem Manufacturing (iBCM), ZJU-Hangzhou Global Scientific and Technological Innovation Center, Hangzhou, 311200, Zhejiang, China. sunwj0102@zju.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH